The U.S. cannabis industry has witnessed the most significant shift in federal policy in decades following the Department of Justice’s (DOJ) recent final order to reschedule certain cannabis products under the Controlled Substances Act (CSA). Effective April 23, 2026, state-licensed medical marijuana has been reclassified from Schedule I to Schedule III. The immediate and most profound consequence of this change is the removal of the decades-long burden of Internal Revenue Code (IRC) Section 280E for qualifying businesses.
The Problem with Section 280E
Prior to this order, all forms of marijuana were classified as Schedule I controlled substances for federal tax purposes, subjecting state-legal cannabis businesses to Section 280E. This provision prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary and necessary business expenses like payroll, rent, and marketing.
The effect of 280E was devastating; businesses were taxed on their gross income rather than their net income, resulting in significantly inflated effective tax rates and, in many cases, after-tax cash losses.
The Immediate Relief: Deducting Expenses
Because Schedule III substances fall outside the scope of Section 280E, the reclassification means that qualifying medical marijuana businesses can now deduct ordinary and necessary business expenses under IRC Section 162, just like any other traditional business. Industry calculations suggest that eliminating 280E could generate between $1.6 billion and $2.2 billion in incremental after-tax cash flow annually across the industry.
Important Limitations and Pending Guidance
While this is a monumental step, the tax implications are not entirely straightforward as federal guidance is forthcoming.
1. Scope of Relief: Medical vs. Recreational
The tax relief, like the rescheduling order itself, currently applies only to two categories:
* Drug products containing marijuana that have been approved by the FDA.
* Marijuana subject to a state-issued license to manufacture, distribute, or dispense for medical purposes.
Recreational (adult-use) cannabis remains classified as Schedule I and is still subject to the 280E deduction disallowance. The DOJ has scheduled a new administrative hearing for June 29, 2026, to consider broader rescheduling that may affect adult-use cannabis.
2. Transition Rules
The Treasury and the IRS have announced that forthcoming guidance is expected to include a transition rule. This rule suggests that, for 280E purposes, rescheduling will apply for a business’s full taxable year that includes the effective date of the final order (i.e., for the entirety of the 2026 tax year).
3. Expense Apportionment
For businesses with licenses covering both medical (Schedule III) and adult-use (Schedule I) activities, guidance is expected to clarify how expenses must be properly apportioned between deductible (medical) and non-deductible (recreational) activities.
4. Retrospective Relief (Prior Years)
The final order encourages the Treasury to “consider providing retrospective relief from Section 280E” for taxable years in which a state licensee operated under a state medical marijuana license. Whether the Treasury will grant this relief for tax years before 2026 is currently unclear. If granted, relief would generally be available only for tax years where the statutes of limitation are still open for the taxpayer, typically three years from the filing date.
Next Steps for Cannabis Businesses
With significant changes now in effect and more guidance on the way, cannabis companies should take proactive steps:
- Evaluate Product and Revenue Streams: Clearly identify which products and activities qualify as Schedule III and which remain subject to Schedule I treatment.
- Review Accounting Systems: Adjust financial models to incorporate standard business deductions. Review inventory, cost capitalization, and depreciation methods to optimize tax planning.
- Model Tax Impact: Model the effect of these changes on estimated taxes, cash tax forecasts, and financial statement tax provisions for the current year.
- Monitor Guidance: Stay alert for forthcoming guidance from the IRS and Treasury, which is expected to clarify transition rules and expense apportionment.
- Consider Amended Returns/Refund Claims: Once guidance is issued, evaluate opportunities to amend prior returns or file refund claims for eligible activities.
Sam Noshirvan, EA
Timberline Tax Group
Phone: (720) 452-2519
Email: snoshirvan@timberlinetax.com